ATE.V - Antibe Therapeutics Inc.

TSXV - TSXV Delayed Price. Currency in CAD

Antibe Therapeutics Inc.

15 Prince Arthur Avenue
Toronto, ON M5R 1B2

Full Time Employees37

Key Executives

NameTitlePayExercisedYear Born
Mr. Daniel Marcel LegaultPres, CEO, Sec. & Director273kN/A1958
Dr. John Lawrence WallaceFounder, Chief Scientific Officer & Director273kN/A1957
Mr. Alain Wilson MBAChief Financial Officer48kN/AN/A
Mr. Scott Curtis M.Eng, CFAVP of Corp. Devel.95kN/AN/A
Dr. David James Vaughan Ph.D.Chief Devel. OfficerN/AN/A1950
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.


Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Corporate Governance

Antibe Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.